Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of two distinct products—vitamin C (ascorbic acid), a dietary supplement and antioxidant, and Femoston, a pharmaceutical hormone replacement therapy (HRT) containing estradiol and dydrogesterone. Vitamin C acts as an essential nutrient with antioxidant properties, supporting immune function, collagen synthesis, and iron absorption. Femoston is used to relieve menopausal symptoms such as hot flushes and prevent postmenopausal osteoporosis in women with an intact uterus; it combines estradiol (an estrogen receptor agonist) to replace declining estrogen levels after menopause, with dydrogesterone (a progestogen receptor agonist) to protect the endometrium from hyperplasia due to unopposed estrogen[1][2][5][6][7]. There are no known fixed-dose combination products marketed under this name; co-administration would be at the discretion of a healthcare provider.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on vitamin c + Femoston.